Bisphosphonates are the mainstay of osteoporosis therapy. Extensive clinical evaluation supports their utility in stemming progression of the disease and in reducing fracture risk. In the course ...

The authors recommend assessment of bone status at commencement and during anastrozole therapy and call for further assessment of the use of bisphosphonates to prevent bone loss in these patients.